Latest News

MSCA 2017 Presidency conference ‘Mobility takes research further’

13 March 2017

Read more ...

aDDRess and CodeAge Final ITN Conference: Abstract book now online!

03 November 2016

Read more ...

Björn Schumacher presentation on BR alpha Campus

7 October 2016

Read more ...

Gallery

gallery prev2

(Click image to open the gallery)

Contact

Let us hear from you.
This email address is being protected from spambots. You need JavaScript enabled to view it. or complete our contact form.

Thanks to

sponsors1sponsors2sponsors3


Dr. Maria Denis
Biomedcode Hellas S.A., Preclinical Drug Evaluation Unit, Greece

Image

Biomedcode Hellas S.A., Preclinical Drug Evaluation Unit

Alexander Fleming Street 34

16672 Vari, Greece
mdenis@biomedcode.com
Tel: +30 210 9655366
www.biomedcode.com

Image

Dr. Maria C. Denis is CEO of Biomedcode Hellas SA since 2010. In 2001, she received her Ph.D. from TUFTS University in Boston, USA, in Immunology in the field of cytokines and their post-translational modification. After graduation and until 2003 she held a post-doctoral position at Harvard Medical School in Boston, USA in the field of type 1 diabetes and until 2009 she held a post-doctoral position at BSRC “Al. Fleming” in Athens, Greece, in the field of chronic inflammatory diseases. In 2009 Dr Denis joined Biomedcode's Scientific Management Team first as Head of Preclinical Services and since March 2010 as Chief Executive Officer.

Research Interests:

Biomedcode Hellas SA is a Contract Research Organization (CRO) providing full preclinical drug evaluation services using a unique collection of mouse models of human inflammatory diseases mimicking Rheumatoid Arthritis, Intestinal Inflammation, Multiple Sclerosis and others. Biomedcode offers a diverse array of advanced evaluation platforms ideal for the preclinical testing of therapeutics. Primary interests of Biomedcode include the development of novel inflammatory disease models, the comprehensive phenotyping of disease progression, the standardization of novel preclinical drug evaluation platforms and the identification of novel disease pathways and biomarkers.